علاج الساركوما الدهنية غير المتمايزة المتقدمة أو المنتقلة

References

DOI: 10.1016/j.ctrv.2024.102846

Anthracycline-based therapy, either as a single agent (doxorubicin or epirubicin) or as part of a combination (doxorubicin or epirubicin in combination with ifosfamide), is considered the front-line standard for metastatic DDLPS.

Pembrolizumab or nivolumab (with or without ipilimumab) are listed in NCCN guidelines for subsequent lines of therapy for advanced or metastatic disease.

Given limited systemic therapy options, we typically incorporate immune checkpoint inhibitors after approved chemotherapies.